{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T12:45:08Z","timestamp":1792154708136,"version":"4.4.0"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003977","name":"Israel Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003977","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.antiviral.2019.104639","type":"journal-article","created":{"date-parts":[[2019,10,22]],"date-time":"2019-10-22T02:04:51Z","timestamp":1571709891000},"page":"104639","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["Artemisone demonstrates synergistic antiviral activity in combination with approved and experimental drugs active against human cytomegalovirus"],"prefix":"10.1016","volume":"172","author":[{"given":"Esther","family":"Oiknine-Djian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shikma","family":"Bar-On","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ido","family":"Laskov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Lantsberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard K.","family":"Haynes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amos","family":"Panet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana G.","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2019.104639_bib1","series-title":"Overview of HCV Life Cycle with a Special Focus on Current and Possible Future Antiviral Targets","author":"Alazard-Dany","year":"2019"},{"key":"10.1016\/j.antiviral.2019.104639_bib2","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0010370","article-title":"Artemisinin-derived dimers have greatly improved anti-cytomegalovirus activity compared to artemisinin monomers","volume":"5","author":"Arav-Boger","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.antiviral.2019.104639_bib3","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.antiviral.2018.09.003","article-title":"New therapies for human cytomegalovirus infections","volume":"159","author":"Britt","year":"2018","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2019.104639_bib4","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.antiviral.2018.07.013","article-title":"Antiviral activity of maribavir in combination with other drugs active against human cytomegalovirus","volume":"157","author":"Chou","year":"2018","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2019.104639_bib5","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.antiviral.2011.07.018","article-title":"The unique antiviral activity of artesunate is broadly effective against human cytomegaloviruses including therapy-resistant mutants","volume":"92","author":"Chou","year":"2011","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2019.104639_bib6","doi-asserted-by":"crossref","first-page":"3470","DOI":"10.1128\/AAC.00577-06","article-title":"Maribavir antagonizes the antiviral action of ganciclovir on human cytomegalovirus","volume":"50","author":"Chou","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2019.104639_bib7","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1128\/AAC.00207-06","article-title":"Effect of cell culture conditions on the anticytomegalovirus activity of maribavir","volume":"50","author":"Chou","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2019.104639_bib8","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.58.3.10","article-title":"Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies","volume":"58","author":"Chou","year":"2006","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.antiviral.2019.104639_bib9","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.coviro.2016.03.004","article-title":"Current status and prospects of HIV treatment","volume":"18","author":"Cihlar","year":"2016","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.antiviral.2019.104639_bib10","doi-asserted-by":"crossref","first-page":"535","DOI":"10.3851\/IMP3028","article-title":"Artesunate demonstrates in vitro synergism with several antiviral agents against human cytomegalovirus","volume":"21","author":"Drouot","year":"2016","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.antiviral.2019.104639_bib11","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s00109-001-0300-8","article-title":"Antiviral activity of artesunate towards wild-type, recombinant, and ganciclovir-resistant human cytomegaloviruses","volume":"80","author":"Efferth","year":"2002","journal-title":"J. Mol. Med."},{"key":"10.1016\/j.antiviral.2019.104639_bib12","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1086\/591195","article-title":"The antiviral activities of artemisinin and artesunate","volume":"47","author":"Efferth","year":"2008","journal-title":"Clin. Infect. Dis. : Off. Publ. Infect. Dis. Soc. Am."},{"key":"10.1016\/j.antiviral.2019.104639_bib13","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0166-3542(02)00094-3","article-title":"Interactions among antiviral drugs acting late in the replication cycle of human cytomegalovirus","volume":"56","author":"Evers","year":"2002","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2019.104639_bib14","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1093\/cid\/cix259","article-title":"Risk factors and outcomes of ganciclovir-resistant cytomegalovirus infection in solid organ transplant recipients","volume":"65","author":"Fisher","year":"2017","journal-title":"Clin. Infect. Dis. : Off. Publ. Infect. Dis. Soc. Am."},{"key":"10.1016\/j.antiviral.2019.104639_bib15","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1093\/jac\/dkt346","article-title":"Stability and antiviral activity against human cytomegalovirus of artemisinin derivatives","volume":"69","author":"Flobinus","year":"2014","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.antiviral.2019.104639_bib16","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.antiviral.2013.10.014","article-title":"Success and failure of artesunate treatment in five transplant recipients with disease caused by drug-resistant cytomegalovirus","volume":"101","author":"Germi","year":"2014","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2019.104639_bib17","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1002\/path.4437","article-title":"The pathogenesis of human cytomegalovirus","volume":"235","author":"Griffiths","year":"2015","journal-title":"J. Pathol."},{"key":"10.1016\/j.antiviral.2019.104639_bib18","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0024334","article-title":"An artemisinin-derived dimer has highly potent anti-cytomegalovirus (CMV) and anti-cancer activities","volume":"6","author":"He","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.antiviral.2019.104639_bib19","doi-asserted-by":"crossref","first-page":"3508","DOI":"10.1128\/AAC.00519-12","article-title":"Artemisinin-derived dimer diphenyl phosphate is an irreversible inhibitor of human cytomegalovirus replication","volume":"56","author":"He","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2019.104639_bib20","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.antiviral.2015.10.003","article-title":"The broad-spectrum antiinfective drug artesunate interferes with the canonical nuclear factor kappa B (NF-kappaB) pathway by targeting RelA\/p65","volume":"124","author":"Hutterer","year":"2015","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2019.104639_bib21","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.antiviral.2005.10.003","article-title":"The anti-malaria drug artesunate inhibits replication of cytomegalovirus in vitro and in vivo","volume":"69","author":"Kaptein","year":"2006","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2019.104639_bib22","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1093\/cid\/ciq050","article-title":"Artesunate is ineffective in controlling valganciclovir-resistant cytomegalovirus infection","volume":"52","author":"Lau","year":"2011","journal-title":"Clin. Infect. Dis. : Off. Publ. Infect. Dis. Soc. Am."},{"key":"10.1016\/j.antiviral.2019.104639_bib23","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1128\/CMR.00009-10","article-title":"Antiviral drug resistance of human cytomegalovirus","volume":"23","author":"Lurain","year":"2010","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.antiviral.2019.104639_bib24","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.coviro.2011.10.011","article-title":"Maribavir and human cytomegalovirus-what happened in the clinical trials and why might the drug have failed?","volume":"1","author":"Marty","year":"2011","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.antiviral.2019.104639_bib25","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","article-title":"Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation","volume":"377","author":"Marty","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2019.104639_bib26","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S1473-3099(11)70024-X","article-title":"Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial","volume":"11","author":"Marty","year":"2011","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.antiviral.2019.104639_bib27","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.bbmt.2018.09.038","article-title":"A randomized, double-blind, placebo-controlled phase 3 trial of oral brincidofovir for cytomegalovirus prophylaxis in allogeneic hematopoietic cell transplantation. Biology of blood and marrow transplantation","volume":"25","author":"Marty","year":"2019","journal-title":"J. Am. Soc. Blood Marrow Transplant."},{"key":"10.1016\/j.antiviral.2019.104639_bib28","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1056\/NEJMoa1303688","article-title":"CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation","volume":"369","author":"Marty","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2019.104639_bib29","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.placenta.2014.11.003","article-title":"Ex vivo model of congenital cytomegalovirus infection and new combination therapies","volume":"36","author":"Morere","year":"2015","journal-title":"Placenta"},{"key":"10.1016\/j.antiviral.2019.104639_bib30","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1128\/AAC.01585-07","article-title":"First assessment in humans of the safety, tolerability, pharmacokinetics, and ex vivo pharmacodynamic antimalarial activity of the new artemisinin derivative artemisone","volume":"52","author":"Nagelschmitz","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2019.104639_bib31","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.antiviral.2018.08.015","article-title":"In vitro evaluation of current and novel antivirals in combination against human cytomegalovirus","volume":"158","author":"O'Brien","year":"2018","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2019.104639_bib32","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00288-18","article-title":"The artemisinin derivative artemisone is a potent inhibitor of human cytomegalovirus replication","volume":"62","author":"Oiknine-Djian","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2019.104639_bib33","doi-asserted-by":"crossref","first-page":"5452","DOI":"10.1016\/j.bmc.2015.07.048","article-title":"Highly potent artemisinin-derived dimers and trimers: synthesis and evaluation of their antimalarial, antileukemia and antiviral activities","volume":"23","author":"Reiter","year":"2015","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.antiviral.2019.104639_bib34","doi-asserted-by":"crossref","first-page":"3870","DOI":"10.1128\/AAC.00262-15","article-title":"Inhibition of human cytomegalovirus replication by artemisinins: effects mediated through cell cycle modulation","volume":"59","author":"Roy","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2019.104639_bib35","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.antiviral.2010.12.002","article-title":"Antiviral activity of ganciclovir and artesunate towards human cytomegalovirus in astrocytoma cells","volume":"89","author":"Schnepf","year":"2011","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2019.104639_bib36","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1086\/587106","article-title":"Artesunate as a potent antiviral agent in a patient with late drug-resistant cytomegalovirus infection after hematopoietic stem cell transplantation","volume":"46","author":"Shapira","year":"2008","journal-title":"Clin. Infect. Dis. : Off. Publ. Infect. Dis. Soc. Am."},{"key":"10.1016\/j.antiviral.2019.104639_bib37","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1093\/infdis\/jit475","article-title":"High rate of cytomegalovirus drug resistance among patients receiving preemptive antiviral treatment after haploidentical stem cell transplantation","volume":"209","author":"Shmueli","year":"2014","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2019.104639_bib38","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01735-18","article-title":"Inhibition of cytomegalovirus replication with extended-half-life synthetic ozonides","volume":"63","author":"Wang","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2019.104639_bib39","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01905-16","article-title":"Zika virus infects early- and midgestation human maternal decidual tissues, inducing distinct innate tissue responses in the maternal-fetal interface","volume":"91","author":"Weisblum","year":"2017","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.104639_bib40","doi-asserted-by":"crossref","first-page":"13204","DOI":"10.1128\/JVI.05749-11","article-title":"Modeling of human cytomegalovirus maternal-fetal transmission in a novel decidual organ culture","volume":"85","author":"Weisblum","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.104639_bib41","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1128\/AAC.00114-15","article-title":"In vitro drug combination studies of Letermovir (AIC246, MK-8228) with approved anti-human cytomegalovirus (HCMV) and anti-HIV compounds in inhibition of HCMV and HIV replication","volume":"59","author":"Wildum","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2019.104639_bib42","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.antiviral.2011.03.184","article-title":"Human cytomegalovirus kinetics following institution of artesunate after hematopoietic stem cell transplantation","volume":"90","author":"Wolf","year":"2011","journal-title":"Antivir. Res."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354219304140?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354219304140?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T12:29:49Z","timestamp":1759062589000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354219304140"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":42,"alternative-id":["S0166354219304140"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2019.104639","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Artemisone demonstrates synergistic antiviral activity in combination with approved and experimental drugs active against human cytomegalovirus","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2019.104639","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104639"}}